Neumora Therapeutics, Inc. (NMRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neumora Therapeutics, Inc. (NMRA) has a cash flow conversion efficiency ratio of -0.353x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.63 Million) by net assets ($132.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NMRA company net worth for the company's overall valuation and market capitalisation.
Neumora Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Neumora Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neumora Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neumora Therapeutics, Inc. ranked by their cash flow conversion efficiency. See NMRA debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FACT II Acquisition Corp. Class A Ordinary Shares
NASDAQ:FACT
|
-0.001x |
|
Apyx Medical Inc
NASDAQ:APYX
|
-0.315x |
|
Cheops Technology France SA
PA:MLCHE
|
N/A |
|
Humacyte Inc
NASDAQ:HUMA
|
-8.403x |
|
Powercell Sweden
ST:PCELL
|
0.015x |
|
Hanla IMS Co. Ltd
KQ:092460
|
-0.023x |
|
Bharat Wire Ropes Limited
NSE:BHARATWIRE
|
0.069x |
|
KB Star REIT Co. Ltd.
KO:432320
|
0.005x |
Annual Cash Flow Conversion Efficiency for Neumora Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Neumora Therapeutics, Inc. from 2019 to 2024. View Neumora Therapeutics, Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $287.06 Million | $-182.94 Million | -0.637x | -83.08% |
| 2023-12-31 | $469.08 Million | $-163.28 Million | -0.348x | -235.38% |
| 2022-12-31 | $-446.85 Million | $-114.90 Million | 0.257x | +10.88% |
| 2021-12-31 | $-325.22 Million | $-75.42 Million | 0.232x | -18.21% |
| 2020-12-31 | $-94.38 Million | $-26.76 Million | 0.284x | -99.98% |
| 2019-12-31 | $-21.00K | $-26.76 Million | 1274.286x | -- |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more